Inhalis Therapeutics SA Achieves Key Milestone with Patent Application Filing

About Inhalis Therapeutics SA About Inhalis Therapeutics SA Inhalis Therapeutics SA is committed to develop breakthrough inhaled treatments for life-threatening disorders. Solid science and industry-leading delivery technology are combined with an experienced management team to research and develop new inhaled treatments for Idiopathic Pulmonary Fibrosis and other diseases. The lead asset, INHAL-101, a ground-breaking solution for IPF, is poised to initiate clinical trials in Q4/2024...

About Inhalis Therapeutics SA

Inhalis Therapeutics SA is committed to develop breakthrough inhaled treatments for life-threatening disorders. Solid science and industry-leading delivery technology are combined with an experienced management team to research and develop new inhaled treatments for Idiopathic Pulmonary Fibrosis and other diseases. The lead asset, INHAL-101, a ground-breaking solution for IPF, is poised to initiate clinical trials in Q4/2024. The company's pipeline also includes INHAL-102, tailored for lung cancer, and additional assets in late-preclinical proof-of-concept stages for oncology, fibrotic diseases and pulmonary infections.

For further information, please contact:

Silvia Panigone, PhD, EMBA
Chief Executive Officer
Inhalis Therapeutics SA
Phone: +41 78 89 89 644
Email: silvia.panigone@inhalis.com 

Logo - https://mma.prnewswire.com/media/2189259/Inhalis_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/inhalis-therapeutics-sa-achieves-key-milestone-with-patent-application-filing-301904677.html